MedTrace Logo

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg

NCT00912145 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-03-28

No results posted yet for this study

Summary

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg.

Conditions

Interventions

DRUG

Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)

Sponsors & Collaborators

Principal Investigators

  • Calvin F. Fuhrmann, M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1996-02-29
Primary Completion
1996-02-29
Completion
1996-02-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912145 on ClinicalTrials.gov